Sarcomas

Administration of fixed-dose CAR T cells followed by escalating doses of UB-TT170 led to changes in cytokine levels in relapsed/refractory osteosarcoma.

Here is your snapshot of all therapeutic options that the FDA approved in October 2024 spanning tumor types.

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.

This roundup includes exclusive insights from 23 clinicians and key data on the top abstracts coming out of the 2024 ESMO Annual Meeting.

Breelyn Wilky, MD, discusses updated efficacy and safety findings following treatment of botensilimab and balstilimab in refractory metastatic sarcoma.

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.

Read about the early-phase sarcoma studies presented at the 2024 ESMO Congress that experts are keeping their eyes on.

The FDA has granted rare pediatric disease designation to LP-184 in malignant rhabdoid tumors, rhabdomyosarcoma, and hepatoblastoma.

R. Lor Randall, MD, FACS, discusses the relationship between poverty, race, ethnicity, and survival outcomes in pediatric nonmetastatic osteosarcoma.

The FDA has approved subcutaneous atezolizumab for use in all indications as the intravenous formulation.

The FDA has granted orphan drug designation to the novel GSK-3β inhibitor elraglusib for the treatment of patients with soft tissue sarcoma.

Elraglusib plus chemotherapy generated early signals of antitumor activity in pediatric patients with relapsed/refractory Ewing and Ewing-related sarcomas.

R. Lor Randall, MD, FACS, highlights key findings from the pivotal MOTION trial of vimseltinib in patients with TGCT.

This list features a snapshot of key August FDA oncology decisions, efforts to integrate health equity into guideline development, and more.

R. Lor Randall, MD, FACS, details how he treats patients with TGCTs and the potential of vimseltinib to join pexidartinib in the treatment landscape.

Here is your snapshot of all therapeutic options that the FDA approved in August 2024 and their clinical implications.

OMX-0407 was safe and displayed activity in advanced solid tumors; dose-expansion cohorts will evaluate the agent in RCC and angiosarcoma.

The FDA has accepted an NDA for vimseltinib for the treatment of patients with tenosynovial giant cell tumor, with a PDUFA date of February 17, 2025.

R. Lor Randall, MD, FACS, details findings from a genetic and epigenetic study showing 5 sarcoma subtypes had EZH2 activity and a shared epigenetic profile.

The FDA cleared the SeCore CDx HLA A Sequencing System as a companion diagnostic for afamitresgene autoleucel in advanced synovial sarcoma.

The FDA has granted accelerated approval to afamitresgene autoleucel for select patients with pretreated unresectable or metastatic synovial sarcoma.

Adam C. Berger, MD, FACS, discusses key messages for oncologists during Sarcoma Awareness Month.

During Sarcoma Awareness Month, Adam C. Berger, MD, FACS, discusses the importance of timely scans and recognizing the symptoms of sarcoma.

The marketing authorization application seeking the approval of vimseltinib for the treatment of tenosynovial giant cell tumor is under EMA review.

Ciara Kelly, MBBCh, BAO, discusses ongoing GIST research for GIST Awareness Day.

Robert Lawrence Randall, MD, FACS, discusses the significance of risk-based therapy in patients with non-rhabdomyosarcoma soft tissue sarcoma.

Pembrolizumab and platinum-based therapy elicited safe and efficacious outcomes in penile squamous cell carcinoma.

In case you missed any, below is a recap of every OncLive On Air episode that aired in May 2024.

R. Lor Randall, MD, FACS, detailed research into the relationship between guideline-concordant care and survival outcomes in patients with osteosarcoma in California.

Prolonged administration of imatinib maintenance therapy for 6 years improved disease-free survival in patients with gastrointestinal stromal tumors.